LATE PCR

Scientists from Stellenbosch University in South Africa have been awarded $131,000 from the National Institutes of Health for the first year of a planned four-year project aimed at developing and evaluating a molecular assay for multi- and extreme-drug-resistant tuberculosis usin

Smiths Detection Diagnostics and Novartis Diagnostics plan to develop and market highly multiplexed assays for a variety of infectious diseases, beginning with a focus on healthcare-associated infections.

Novartis Diagnostics will take the Bio-Seeq molecular diagnostic tests for infectious disease through clinical trials and on to commercialization.

The company will use $2.2 million to develop a PCR-based multiple flu test.

The UK-based company will offer the toolkit through a single license that combines IP it licensed from Brandeis University and PHRI Properties, the tech-transfer arm of the University of Medicine and Dentistry of New Jersey.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.